Transcatheter aortic valve implantation (TAVI) has become the therapy of choice for treating severe aortic stenosis in patients at high-risk for surgery or where it is considered too risky to attempt. We sought to evaluate the potential cost and clinical impact of TAVI in intermediate risk patients from a French collective perspective.
GOODALL, G., LAMOTTE, M., RAMOS, S., MAUNOURY, F., PEJCHALOVA, B. and DE POUVOURVILLE, G. (2018). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. Journal of Medical Economics, 22(4), pp. 289-296.